Igor Khelemsky, MD
Neurology · Brooklyn, NYNPI 1962431148
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 361 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,857 and has fallen 60.0% since, to $742 in 2025.
Across 361 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Pfizer$1K
- Biohaven Pharmaceuticals, Inc.$660
- Biohaven Pharmaceutical Holding Company Ltd.$610
- Novartis$523
- Lilly USA, LLC$470
- plus $3K from 26 others
What the payments were for
- Speaking & faculty fees$250%
- Food & beverage$7,53899%
- Education$761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 80 | $1,591 |
| Pfizer | 53 | $1,115 |
| Biohaven Pharmaceuticals, Inc. | 27 | $660 |
| Biohaven Pharmaceutical Holding Company Ltd. | 34 | $610 |
| Novartis | 25 | $523 |
| Lilly USA, LLC | 22 | $470 |
| Amgen | 14 | $358 |
| Teva Pharmaceuticals USA, Inc. | 14 | $332 |
| Scilex Pharmaceuticals Inc. | 14 | $317 |
| Bristol Myers Squibb | 15 | $302 |
| Biogen | 10 | $193 |
| Amneal Pharmaceuticals LLC | 8 | $184 |
| Neurocrine Biosciences, Inc. | 5 | $127 |
| Medtronic | 2 | $101 |
| Lundbeck LLC | 4 | $91 |
| Upsher-smith Laboratories LLC | 3 | $68 |
| Kowa Pharmaceuticals America, Inc. | 5 | $68 |
| Endo Pharmaceuticals Inc. | 3 | $60 |
| MDD US Operations, LLC | 3 | $53 |
| Merck | 3 | $51 |
| Ipsen Biopharmaceuticals, Inc | 2 | $50 |
| Sanofi | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Eisai Inc. | 2 | $36 |
| Neurelis, Inc. | 1 | $34 |
| AstraZeneca | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Harmony Biosciences LLC | 1 | $25 |
| SK Life Science, Inc. | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Avion Pharmaceuticals | 1 | $20 |
| GE HealthCare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$124
- EMGALITY$111
How this compares
$7,640 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 659 | $1,118,263 |
| Emgality PenGalcanezumab-Gnlm | 406 | $274,444 |
| UbrelvyUbrogepant | 168 | $227,404 |
| Aimovig AutoinjectorErenumab-Aooe | 254 | $191,996 |
| QuliptaAtogepant | 152 | $166,170 |
| Diclofenac Sodium | 207 | $117,852 |
| BotoxOnabotulinumtoxina | 78 | $99,018 |
| TecfideraDimethyl Fumarate | 11 | $97,545 |
| Doxepin Hcl | 91 | $75,938 |
| Dihydroergotamine Mesylate | 32 | $68,841 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 72 | $54,409 |
| ZtlidoLidocaine | 95 | $38,908 |
| NeurontinGabapentin | 12 | $28,888 |
| NamzaricMemantine Hcl/Donepezil Hcl | 38 | $24,034 |
| Budesonide ErBudesonide | 19 | $22,311 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $1,115 | $1,118,263659 claims |
| AbbVieUbrelvy, Qulipta, Botox, Namzaric, Linzess | $1,591 | $528,820459 claims |
| BiogenTecfidera | $193 | $97,54511 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $317 | $38,90895 claims |
| Eisai Inc.Fycompa | $36 | $16,23314 claims |
| Amneal Pharmaceuticals LLCRytary | $184 | $10,11530 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,623 neurology providers in New York.
Other neurology in Brooklyn
- Idan SharonBrooklyn$2.1M
- Karen Blitz ShabbirBrooklyn$220K
- Allan PerelStaten Island$1.7M
- Nicolas SaikaliAmherst$1.5M
- David KreitzmanCommack$1.5M
- Charles ArgoffAlbany$1.2M
- Stephen KriegerNew York$1.1M
- Robert FeketeHawthorne$1M
- Jennifer McVigeAmherst$982K
- Warren SpinnerPort Jefferson Station$791K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.